The balance sheet is increasingly fragile, with goodwill accounting for $68.7 million of the $72.3 million in total assets as of 2026Q2, while the current ratio has deteriorated to 0.32.
| Metric | TTM | Sep'25 | Sep'24 | Sep'23 | Sep'22 | Sep'21 | Sep'20 | Sep'19 | Sep'18 | Sep'17 | Sep'16 | Sep'15 | Sep'14 | Sep'13 | Sep'12 | Sep'11 | Sep'10 | Sep'07 | Sep'05 |
|---|
| Total Current Assets | 3.42M | 9.76M | 3.11M | 8.02M | 12.59M | 12.26M | 4.3M | 1.98M | 1.48M | 1.05M | 1.31M | 947.71K | 1.35M | 2.44M | 2.75M | 1.66M | 1.65M | 5.63K | 519.01K |
| Cash & Short-Term Investments | 2.04M | 8.82M | 3.11M | 8.02M | 12.59M | 12.26M | 4.3M | 1.9M | 934.41K | 103.18K | 188.31K | 82.27K | 70.39K | 747.13K | 1.14M | 92.31K | 83.94K | 91 | 519.01K |
| Cash Only | 2.04M | 8.82M | 3.11M | 8.02M | 12.59M | 12.26M | 4.3M | 1.9M | 934.41K | 103.18K | 188.31K | 82.27K | 70.39K | 747.13K | 0 | 92.31K | 83.94K | 0 | 0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 63.05K | 320.54K | 693.32K | 808.96K | 619.85K | 845.05K | 1.04M | 1.04M | 832.8K | 892.15K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | 12.75 | 27.19 | 51.92 | 49.02 | 35.96 | 38.64 | 44.15 | 48 | 33.27 | 128.07 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.1K | 203.58K | 225.91K | 295.22K | 217.82K | 412.83K | 600.79K | 344.69K | 454.59K | 622.77K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 1.77 | 20.98 | 20.59 | 21.13 | 14.13 | 21.19 | 30.79 | 19.64 | 20.86 | 108.48 | - | - |
| Other Current Assets | 903.02K | 708.17K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 68.85M | 115.32M | 553.67K | 242.18K | 1.16M | 631.27K | 383.97K | 662.21K | 624.28K | 138.27K | 1.32M | 1.51M | 1.87M | 2.19M | 2.57M | 2.65M | 2.49M | 83.16K | 16.72K |
| Property, Plant & Equipment | 154.89K | 253.9K | 404.5K | 226.41K | 1.15M | 617.51K | 257.67K | 374K | 169.33K | 133.2K | 285.42K | 366.25K | 447.24K | 427.21K | 469K | 522.67K | 588.06K | 0 | 9.85K |
| Fixed Asset Turnover | 0.00x | - | - | - | 3.79x | - | 0.47x | 4.83x | 25.41x | 36.59x | 21.10x | 17.18x | 17.85x | 20.07x | 16.90x | 17.48x | 4.32x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 983.64K | 983.64K | 983.64K | 983.64K | 983.64K | 983.64K | 983.64K | 0 | 0 |
| Intangible Assets | 68.67M | 115.04M | 0 | 0 | 0 | 0 | 101.11K | 274.45K | 447.78K | 0 | 43.75K | 158K | 431.65K | 770.88K | 1.11M | 1.14M | 918.07K | 0 | 6.88K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 0 | 0 |
| Other Non-Current Assets | 24.17K | 24.17K | 149.17K | 15.77K | 13.77K | 13.77K | 25.18K | 13.77K | 7.17K | 5.07K | 5.07K | 5.07K | 5.07K | 6.16K | 6.16K | 1.09K | 1.09K | 83.16K | 0 |
| Total Assets | 72.28M | 125.08M | 3.66M | 8.27M | 13.76M | 12.89M | 4.68M | 2.64M | 2.1M | 1.19M | 2.63M | 2.46M | 3.22M | 4.63M | 5.32M | 4.31M | 4.14M | 88.78K | 535.73K |
| Asset Turnover | 0.00x | - | - | - | 0.32x | - | 0.03x | 0.68x | 2.05x | 4.10x | 2.29x | 2.56x | 2.48x | 1.85x | 1.49x | 2.12x | 0.61x | - | - |
| Asset Growth % | 16905.39% | 3313.34% | -55.67% | -39.92% | 6.74% | 175.29% | 77.38% | 25.52% | 76.96% | -54.83% | 6.92% | -23.6% | -30.42% | -12.98% | 23.33% | 4.08% | 4567.68% | -83.43% | - |
| Total Current Liabilities | 10.68M | 3.74M | 5.16M | 4.52M | 3.81M | 11.47M | 6.57M | 5.82M | 4.71M | 5.15M | 5.44M | 7.84M | 6.63M | 7.39M | 5.11M | 4.87M | 4.32M | 1.14M | 133.41K |
| Accounts Payable | 2.91M | 1.83M | 552.68K | 1.29M | 526.97K | 419.09K | 493.5K | 817.99K | 1.52M | 2.16M | 2.03M | 2.52M | 2.3M | 2.37M | 1.67M | 1.21M | 1.58M | 793.18K | 133.41K |
| Days Payables Outstanding | 18.21K | - | 746.68 | 1.51K | 599.21 | 761.77 | 576.01 | 203.88 | 157.11 | 196.83 | 144.97 | 163.46 | 118.07 | 121.3 | 95.03 | 55.71 | 275.56 | - | - |
| Short-Term Debt | 5.09M | 88.43K | 4.32M | 2.92M | 2.47M | 9.74M | 4.3M | 4.08M | 2.4M | 1.74M | 2.08M | 1.27M | 1.46M | 753.13K | 2.38M | 2.71M | 1.8M | 50.75K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 55.96K | 63.9K | 0 | 5.83K | 0 | 0 | 666.67K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.68M | 724.25K | 0 | 312.4K | 811.2K | 1.31M | 1.78M | 918.56K | 729.69K | 1.19M | 1.33M | 4.04M | 2.87M | 4.26M | 397.16K | 939K | 935.65K | 297.84K | 0 |
| Current Ratio | 0.32x | 2.61x | 0.60x | 1.77x | 3.31x | 1.07x | 0.65x | 0.34x | 0.31x | 0.20x | 0.24x | 0.12x | 0.20x | 0.33x | 0.54x | 0.34x | 0.38x | 0.00x | 3.89x |
| Quick Ratio | 0.32x | 2.61x | 0.60x | 1.77x | 3.31x | 1.07x | 0.65x | 0.34x | 0.27x | 0.16x | 0.19x | 0.09x | 0.14x | 0.25x | 0.47x | 0.25x | 0.24x | 0.00x | 3.89x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | -189.36 | -108.94 | -124.32 | -74.82 | -113.37 | -58.25 | -46.37 | -27.39 | -1.58 | -39.01 | - | - |
| Total Non-Current Liabilities | 1.7M | 24.22M | 657.25K | 0 | 87.12K | 178.17K | 23.25K | 121.61K | 0 | 0 | 0 | 0 | 0 | 1.89K | 4.01K | 1.01M | 1.68M | 425.34K | 0 |
| Long-Term Debt | 0 | 0 | 407.52K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.01K | 983.37K | 1.62M | 425.34K | 0 |
| Capital Lease Obligations | 602.57K | 172.25K | 249.73K | 0 | 87.12K | 178.17K | 23.26K | 121.61K | 0 | 0 | 0 | 0 | 0 | 1.89K | 0 | 31.22K | 54.44K | 0 | 0 |
| Deferred Tax Liabilities | 33.93M | 24.05M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 12.38M | 27.96M | 5.82M | 4.52M | 3.9M | 11.65M | 6.6M | 5.94M | 4.71M | 5.15M | 5.44M | 7.84M | 6.63M | 7.39M | 5.12M | 5.88M | 6M | 1.57M | 133.41K |
| Total Debt | 5.21M | 342.79K | 5.08M | 2.92M | 2.56M | 9.91M | 4.33M | 4.2M | 2.4M | 1.74M | 2.08M | 1.27M | 1.46M | 755.02K | 2.39M | 3.73M | 3.48M | 476.09K | 0 |
| Net Debt | 3.18M | -8.48M | 1.97M | -5.11M | -10.04M | -2.34M | 27.6K | 2.3M | 1.47M | 1.63M | 1.89M | 1.19M | 1.39M | 7.89K | 2.39M | 3.63M | 3.39M | 476.09K | 0 |
| Debt / Equity | 0.09x | 0.00x | - | 0.78x | 0.26x | 7.98x | - | - | - | - | - | - | - | - | 11.79x | - | - | - | - |
| Debt / EBITDA | -0.12x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.07x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -235.30x | -6.87x | -10.06x | -35.99x | -1.57x | -0.70x | -1.12x | -1.70x | -1.89x | -5.99x | -8.31x | -13.69x | -24.44x | -22.48x | -4.79x | -10.63x | -7.11x | -22.53x | -68.36x |
| Total Equity | 59.9M | 97.12M | -2.16M | 3.74M | 9.86M | 1.24M | -1.91M | -3.3M | -2.61M | -3.96M | -2.81M | -5.38M | -3.41M | -2.76M | 202.42K | -1.57M | -1.85M | -1.48M | 402.32K |
| Equity Growth % | 7900.77% | 4604.18% | -157.59% | -62.04% | 693.99% | 164.87% | 41.92% | -26.45% | 34.16% | -40.98% | 47.76% | -57.79% | -23.59% | -1462.46% | 112.92% | 15.4% | -25.26% | -467.45% | - |
| Book Value per Share | 0.15 | 1.54 | -1.00 | 3.02 | 9.77 | 1.69 | -3.52 | -7.31 | -12.08 | -41.21 | -78.66 | -190.11 | -122.95 | -134.61 | 18.53 | -220.24 | -361.61 | -532.35 | 140.18 |
| Total Shareholders' Equity | 59.9M | 97.12M | -2.16M | 3.74M | 9.86M | 1.24M | -1.91M | -3.3M | -2.61M | -3.96M | -2.81M | -5.38M | -3.41M | -2.81M | 170.62K | -1.61M | -1.9M | -1.48M | 402.32K |
| Common Stock | 388.14K | 388.14K | 108.02K | 80.36K | 48.16K | 35.17K | 24.81K | 18.37K | 17.53K | 4.66K | 2.36K | 1.16K | 168.16K | 165.26K | 90.99K | 49.07K | 38.23K | 16.85K | 16.31K |
| Retained Earnings | -216.1M | -163.09M | -138.74M | -121.84M | -101.4M | -81.33M | -55.97M | -42.4M | -34.79M | -31.53M | -27.07M | -24.17M | -21.54M | -20.54M | -13.92M | -11.18M | -8.77M | -5.73M | -3.06M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49.07K | 31.81K | 43.83K | 48.58K | 0 | 0 |
Capital Dilution and Insolvency
As reported in financial statements, USBC's balance sheet has undergone significant volatility, with total assets dropping from $125.1 million in 2025Q4 to $72.3 million by 2026Q2, reflecting a rapid depletion of resources that underscores the company's precarious financial trajectory as a pre-revenue R&D entity.
The sharp contraction in asset value suggests that the company is struggling to maintain its capital base while funding ongoing research. Investors should monitor the persistent accumulation of negative retained earnings, which reached $216.1 million, indicating that the business model has yet to achieve any semblance of self-sustaining operational viability.
Based on recent SEC filings, the company's asset base is heavily skewed toward goodwill, which accounted for $68.7 million of the $72.3 million in total assets as of 2026Q2, leaving minimal tangible assets to support the firm's long-term R&D and hardware development objectives.
The reliance on goodwill as the primary asset component suggests that the company's valuation is tied to intangible expectations rather than physical infrastructure. This composition warrants further investigation, as any impairment of these intangible assets could lead to a catastrophic write-down of the company's reported book value.
According to quarterly data, USBC's current ratio plummeted to 0.32 in 2026Q2 from 2.61 in 2025Q4, signaling a severe tightening of liquidity that leaves the firm with limited buffers to cover its immediate operational obligations and ongoing clinical trial expenses.
The rapid decline in the current ratio suggests that the company is consuming its cash reserves at an unsustainable pace. Without a clear path to revenue, this liquidity crunch may force management to seek further dilutive financing, which would likely exacerbate the existing pressure on shareholder equity.
As indicated by the company's balance sheet, equity has been consistently eroded by massive accumulated deficits, with retained earnings falling to negative $216.1 million in 2026Q2, a trend that highlights the significant value destruction inherent in the firm's long-term, pre-revenue R&D-focused capital allocation strategy.
The negative equity position observed in several prior quarters suggests that the company has historically relied on external capital injections to remain solvent. Investors should be wary of the potential for continued share dilution, as the company appears to have no internal mechanism for generating the equity required to fund its operations.
Quick answers to the most common questions about buying USBC stock.
As of 2025, USBC, Inc. (USBC) had total assets of $125.1M including $9.8M in current assets.
USBC, Inc. (USBC) carries total debt of $0.3M, offset by $8.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
USBC, Inc. (USBC) has total shareholders' equity (book value) of $97.1M ($1.54 book value per share). Book value represents the net worth of the company belonging to common stock holders.
USBC, Inc. (USBC) reported a current ratio of 2.61x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.